{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":7,"podcast":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03581786\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["toripalimab"]],"indication":"recurrent or metastatic nasopharyngeal carcinoma","name":"JUPITER-02","nct_id":"NCT03581786","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=jupiter-02-nct03581786. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years","label":"placebo combine with chemotherapy","type":"PLACEBO_COMPARATOR"},{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years","label":"TORIPALIMAB INJECTION(JS001 )combine with chemotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-11-18","type":"ACTUAL"},"conditions":["Recurrent or Metastatic NPC"],"enrollment":{"count":289,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy","otherNames":[],"type":"BIOLOGICAL"},{"name":"Placebos","otherNames":[],"type":"DRUG"}],"last_update":"2025-09-02","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","official_title":"A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-05-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1","timeFrame":"up to 2 years"}],"references":[{"citation":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181.","pmid":"38015220","type":"DERIVED"},{"citation":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Liu Z, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Feng H, Yao S, Keegan P, Xu RH. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021 Sep;27(9):1536-1543. doi: 10.1038/s41591-021-01444-0. Epub 2021 Aug 2.","pmid":"34341578","type":"DERIVED"}],"start_date":{"date":"2018-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer","url":"https://clinicaltrials.gov/study/NCT03581786"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/jupiter-02-nct03581786"}